OHDSI Home
|
Forums
|
Wiki
|
Github
Researchers
Dexamethasone Cohort Building
(4)
Cohort pathway: the unreasonable proporation
(3)
Hematology projects?
(3)
CohortMethod user group
(
2
3
4
)
(73)
Cohort pathway: why Persons with pathways portion are not equal to 100%?
(5)
Empty cohort issue only occurred on KNN, Naive Bayes, Neural Network, DeepNN model
(5)
Atlas: How to set index date to absolute day or to get_todays_date()
(4)
Negative information in OMOP CDM
(11)
Atlas Cohort Definition (Eligibility requirement of more than 1 occurrence of a diagnosis)
(4)
Research Collaboration: NANOTIZED HERBAL MEDICINE FOR BURNS- FROM CONCEPT TO APPLICATION
(1)
Feature Analysis/Cohort Characterization Tool in ATLAS
(3)
COVID-19 study-a-thon data
(1)
COVID-19 infections in cancer patients
(12)
[COVID-19] Prior immunization as protective for COVID-19 disease/bad outcomes
(3)
[OHDSI Covid19] Literature review on viral prediction models
(
2
)
(23)
Forming external controls for comparative effectiveness estimation
(3)
Do your Rx dispensation data have refills? (USA vs other countries)
(6)
[Covid-19] Alpha-1 blocker as potential prophylaxis against ARDS
(
2
)
(22)
The result with fact_relationship table for antibiotics sensitivity test
(6)
Estimation error: what is the mean of "Currently only MDRR for Cox is supported" when using atlas to do estimation?
(6)
Study on readmission rates and complications after COVID-19 hospitalisation
(10)
COVID and AKI
(
2
)
(30)
Is it possible to run a simple vocabulary query without having to download OMOP
(2)
Definitions for Covid-19 severity - mild, moderate, severe
(7)
Validation set- How can I identify COVID19 patients?
(3)
Question about the concept set for "Cohort #279, Persons hospitalized with COVID-19, broad, w/ prior observation"
(3)
Survey on how you use or make concept sets
(5)
[OHDSI COVID-19] Review on the effect of ACE inhibitors and Angiotensin Receptor Blockers on COVID-19 incidence and complication rate
(
2
)
(29)
Network study: Concept Prevalence
(
2
)
(27)
[OHDSI Covid19] Literature review on Covid19 characterization
(
2
)
(22)
← previous page
next page →
t